Endocrine Pharmacology Practice Questions

Q: Which of the following statements about acarbose is incorrect?

It does not delay the progression of diabetes.. Phase 1: it does not delay the progression of diabetes - This statement is **incorrect** - clinical studies, particularly the **STOP-NIDDM trial**, have demonstrated that acarbose **can delay the progression from impaired glucose tolerance (IGT) to type 2 diabetes**. - Acarbose's mechanism of reducing postprandial glucose fluctuations helps in **beta-cell preservation** and improves insulin sensitivity, thereby modifying disease progression. - This is a well-established benefit of acarbose beyond just glycemic control. *It is an alpha-glucosidase inhibitor* - This is a **correct** statement - acarbose is indeed an **alpha-glucosidase inhibitor** that works in the small intestine [1]. - It inhibits enzymes that break down complex carbohydrates, thereby delaying glucose absorption and reducing postprandial glucose spikes [1], [3]. *It decreases fibrinogen levels* - While acarbose does not have a **direct, primary pharmacological effect** on fibrinogen levels, this statement is debatable. - Improved glycemic control with any antidiabetic agent can have indirect effects on various cardiovascular markers over time. - However, decreasing fibrinogen is not a recognized clinical indication or primary mechanism of acarbose [2]. *Controls both pre and post prandial hyperglycemia* - This is largely **correct** - acarbose is most effective at controlling **postprandial hyperglycemia** by delaying carbohydrate digestion and absorption [3]. - While its primary and strongest effect is on post-meal glucose spikes, improved overall glycemic control can contribute to modest improvements in fasting glucose levels as well.

Q: All of the following are uses of octreotide except for which of the following?

Hepatic encephalopathy. ***Hepatic encephalopathy*** - **Octreotide is not typically used for hepatic encephalopathy**. Treatment focuses on reducing ammonia levels, often with **lactulose** or **rifaximin**. - Its mechanism of action (somatostatin analog) does not directly address the pathophysiology of hepatic encephalopathy. *Secretory diarrhea* - Octreotide is highly effective in treating **secretory diarrhea**, especially in cases related to tumors such as **VIPomas** or **carcinoid syndrome** [1, 2]. - It reduces intestinal fluid and electrolyte secretion by mimicking the action of **somatostatin**. *Acromegaly* - Octreotide is a primary treatment for **acromegaly**, a condition caused by excessive growth hormone production [1, 2]. - It suppresses the secretion of **growth hormone (GH)** and **insulin-like growth factor 1 (IGF-1)** from the pituitary gland [1, 2]. *Bleeding esophageal varices* - Octreotide is used to manage acute bleeding from **esophageal varices** by causing splanchnic vasoconstriction [1, 2]. - This action reduces **portal venous pressure**, thereby decreasing blood flow to the varices and stemming the hemorrhage.

Q: Which of the following drugs is a corticosteroid and not used for treating glaucoma?

Prednisolone. ***Prednisolone*** - **Prednisolone** is a potent **corticosteroid** used to reduce inflammation. - While it has various therapeutic uses, **corticosteroids** can cause or worsen **glaucoma** by increasing intraocular pressure and are therefore generally avoided in its treatment. *Brimonidine* - **Brimonidine** is an **alpha-2 adrenergic agonist** used to treat **glaucoma** by reducing aqueous humor production and increasing uveoscleral outflow. - It is not a corticosteroid and directly targets **intraocular pressure (IOP)** reduction. *Dorzolamide* - **Dorzolamide** is a **carbonic anhydrase inhibitor** that effectively treats **glaucoma** by decreasing aqueous humor secretion. - It works by inhibiting the enzyme **carbonic anhydrase** in the ciliary body, and it is not a corticosteroid. *Timolol* - **Timolol** is a **non-selective beta-blocker** that lowers **intraocular pressure** by reducing the production of aqueous humor. - It is one of the most commonly prescribed drugs for **glaucoma** and is not a corticosteroid.

Q: Which of the following antidiabetic drugs is NOT an insulin secretagogue?

Pramlintide. ***Pramlintide*** - **Pramlintide** is an **amylin analog** which delays gastric emptying, suppresses glucagon secretion, and promotes satiety, thereby reducing postprandial glucose. It is **not an insulin secretagogue**. - Its mechanism of action is distinct from drugs that directly stimulate insulin release from pancreatic beta cells. - **This is the correct answer** as pramlintide has no role in enhancing insulin secretion. *Exenatide* - **Exenatide** is a **glucagon-like peptide-1 (GLP-1) receptor agonist** that enhances **glucose-dependent** insulin secretion. - Unlike traditional insulin secretagogues (sulfonylureas and glinides), GLP-1 agonists work through the **incretin effect** and only stimulate insulin release when glucose levels are elevated. - In strict pharmacological classification, GLP-1 agonists are **incretin mimetics**, not traditional insulin secretagogues, as they do not cause insulin release independent of glucose levels. - However, they do enhance insulin secretion in a physiological manner. *Glinides* - **Glinides**, such as repaglinide and nateglinide, are **insulin secretagogues** that stimulate rapid and short-lived insulin release from pancreatic beta cells. - They bind to the **sulfonylurea receptor** on beta cells, leading to membrane depolarization and insulin exocytosis. - Unlike GLP-1 agonists, glinides can cause insulin release **regardless of glucose levels**. *Sulfonylureas* - **Sulfonylureas**, such as glyburide and glipizide, are **insulin secretagogues** that stimulate insulin secretion by binding to the sulfonylurea receptor on pancreatic beta cells. - This binding leads to **closure of ATP-sensitive potassium channels**, membrane depolarization, and subsequent insulin release, regardless of blood glucose levels. - This glucose-independent action increases the risk of hypoglycemia compared to incretin-based therapies.

Q: What is the primary mechanism of action of propylthiouracil in the treatment of hyperthyroidism?

Inhibits iodine organification. ***Inhibits iodine organification*** - **Propylthiouracil (PTU)** primarily acts by blocking the enzyme **thyroid peroxidase (TPO)**, which catalyzes multiple steps in thyroid hormone synthesis. - TPO is responsible for the **oxidation of iodide and its incorporation into tyrosine residues** on thyroglobulin (organification). - By inhibiting TPO, PTU prevents the **iodination of tyrosine residues**, which is the first enzymatic step in thyroid hormone synthesis. - This is conventionally considered the primary mechanism as organification must occur before coupling can take place. *Inhibits the synthesis of thyroglobulin* - While thyroglobulin is essential for thyroid hormone production, PTU does not directly inhibit its synthesis. - PTU's action is on the enzymatic modification of already synthesized thyroglobulin, not on thyroglobulin production itself. *Inhibits the release of thyroid hormones T4 and T3* - This is primarily the mechanism of action of **iodides** (e.g., Lugol's solution), which block the release of preformed hormones from the thyroid gland via the Wolff-Chaikoff effect. - PTU's main effect is on synthesis, not release, although prolonged use can indirectly reduce stored hormone levels. *Inhibits the coupling of iodinated tyrosine residues* - PTU does inhibit the coupling of **monoiodotyrosine (MIT)** and **diiodotyrosine (DIT)** to form T3 and T4, as this reaction is also catalyzed by thyroid peroxidase. - However, since organification (iodination) must occur **before** coupling can take place, inhibition of organification is considered the **primary rate-limiting step**. - Both effects result from the same mechanism: **inhibition of thyroid peroxidase**.

Q: Non-hormonal drug to prevent postmenopausal osteoporosis is:

Alendronate. ***Alendronate*** - **Alendronate** is a **bisphosphonate**, a class of non-hormonal drugs that inhibit **osteoclast** activity, thereby reducing bone resorption and increasing bone density. - It is a first-line treatment for **postmenopausal osteoporosis** and is effective in preventing fractures. *Estrogen* - **Estrogen** is a **hormonal therapy** used to prevent postmenopausal osteoporosis. - However, its use is associated with increased risks of **thromboembolism**, stroke, and certain cancers. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)**. - While it has estrogen-like effects on bone, it is technically considered a **hormonal agent** because its mechanism of action involves interacting with estrogen receptors. *Teriparatide* - **Teriparatide** is a **parathyroid hormone (PTH) analog**, making it a **hormonal agent** that stimulates **osteoblast** activity to promote new bone formation. - It is an anabolic agent typically reserved for severe osteoporosis or those who have failed other therapies due to its injectable administration and higher cost.

Q: The combined estrogen-progestin pill acts mainly by:

Suppression of FSH and LH release. ***Suppression of FSH and LH release*** - The **estrogen** and **progestin** components of combined oral contraceptives exert a negative feedback on the **hypothalamus** and **pituitary gland**. - This leads to the suppression of **follicle-stimulating hormone (FSH)** and **luteinizing hormone (LH)**, which prevents **ovarian follicle development** and **ovulation**. *Making the endometrium less suitable for implantation* - While combined oral contraceptives do make the **endometrium** less receptive, this is a **secondary mechanism** and not the primary way they prevent pregnancy. - The endometrial changes primarily serve as a **backup plan** if ovulation accidentally occurs. *Enhancing uterine contraction to dislodge the fertilized ovum* - Combined oral contraceptives do **not enhance uterine contractions** to dislodge a fertilized ovum. - This mechanism is generally associated with methods like certain **emergency contraceptives** or early abortion methods. *Thickening of cervical mucus to prevent sperm penetration* - This is a significant effect of the **progestin component**, but it is also a **secondary mechanism** of action for combined pills. - While crucial for contraception, the **primary mechanism** remains the inhibition of ovulation.

Q: Which of the following describes the mechanism of action of acarbose?

It acts by inhibiting the enzyme alpha-glucosidase. ***It acts by inhibiting the enzyme alpha-glucosidase*** - **Acarbose** is an **alpha-glucosidase inhibitor**, which means it blocks the action of enzymes located in the brush border of the small intestine. - This inhibition delays the digestion of **complex carbohydrates** into absorbable monosaccharides, thereby slowing glucose absorption. *It reduces post prandial hyperglycemia* - While **acarbose** does reduce **postprandial hyperglycemia**, this is a **clinical effect** of the drug rather than its fundamental mechanism of action. - The reduction in blood glucose occurs *because* of its inhibitory action on alpha-glucosidase, not as the primary mechanism itself. *It decreases the progression of impaired tolerance to overt diabetes mellitus* - This is an observed **long-term benefit** of acarbose use, particularly in individuals with impaired glucose tolerance, but it is not its **direct pharmacological mechanism**. - This effect results from the sustained improvement in glucose control, reducing the stress on pancreatic beta cells. *It can cause hypoglycemia* - **Acarbose** alone generally **does not cause hypoglycemia** because its action is localized to the gut, delaying carbohydrate absorption rather than increasing insulin secretion or glucose uptake. - However, hypoglycemia can occur if acarbose is taken in combination with other anti-diabetic medications that *do* increase insulin levels (e.g., sulfonylureas or insulin).

Q: The choice of drug for hyperthyroidism in the first trimester of pregnancy is?

Propylthiouracil. ***Propylthiouracil*** - **Propylthiouracil (PTU)** is the preferred treatment for hyperthyroidism during the **first trimester of pregnancy** due to a lower risk of teratogenicity compared to methimazole [1]. [2] - While PTU can cause **liver toxicity**, the risk of birth defects with methimazole in the first trimester is generally considered greater [2]. *Methimazole* - **Methimazole** is generally avoided in the first trimester because it is associated with a higher risk of **congenital anomalies**, specifically **aplasia cutis** and **esophageal atresia**. - It becomes the preferred choice in the **second and third trimesters**, as its side effect profile for the mother is often more favorable [1]. *Carbimazole* - **Carbimazole** is a prodrug that is converted to **methimazole** in the body, and therefore shares the same teratogenic risks as methimazole in the first trimester [2]. - It is also generally avoided during early pregnancy due to the risk of **fetal malformations**. *Perchlorate* - **Perchlorate** can be used to treat hyperthyroidism, but it is not typically a first-line drug, especially in pregnancy. - Its mechanism involves blocking **iodide uptake** into the thyroid gland, but it is associated with potential side effects and other treatment options are generally preferred due to their better-established safety profiles in pregnancy.

Q: A 15-year-old girl with type 1 diabetes is brought to the emergency department complaining of dizziness. Laboratory findings include severe hyperglycemia, ketoacidosis, and a blood pH of 7.15. To achieve rapid control of severe ketoacidosis, which of the following is the most appropriate drug?

Regular insulin. ***Regular insulin*** - **Regular insulin** is a **short-acting insulin** that can be administered intravenously, allowing for rapid onset and precise titration, which is crucial for managing severe **ketoacidosis**. - Intravenous regular insulin is the cornerstone of **diabetic ketoacidosis (DKA)** treatment, as it quickly lowers blood glucose and suppresses ketogenesis. *NPH insulin* - **NPH (Neutral Protamine Hagedorn) insulin** is an **intermediate-acting insulin** and is not suitable for the rapid control required in DKA. - Its delayed onset and prolonged duration make it inappropriate for acute emergency management of severe hyperglycemia and ketoacidosis. *Tolbutamide* - **Tolbutamide** is an oral sulfonylurea used to stimulate insulin secretion in patients with **type 2 diabetes** who still have some pancreatic beta-cell function. - It is ineffective in **type 1 diabetes** where there is an absolute insulin deficiency, and it does not provide rapid insulin action for DKA. *Ultralente insulin* - **Ultralente insulin** is a **long-acting insulin** that is no longer widely used and has a very slow onset and prolonged duration of action. - It is unsuitable for the acute management of severe ketoacidosis, which requires rapid and titratable insulin delivery.

Question 1

Which of the following statements about acarbose is incorrect?

Accepted Answer

It does not delay the progression of diabetes.

Answer

It is an alpha-glucosidase inhibitor.

Answer

Controls both pre and post prandial hyperglycemia.

Answer

It decreases fibrinogen levels.

Question 2

All of the following are uses of octreotide except for which of the following?

Accepted Answer

Hepatic encephalopathy

Answer

Secretory diarrhea

Answer

Acromegaly

Answer

Bleeding esophageal varices

Question 3

Which of the following drugs is a corticosteroid and not used for treating glaucoma?

Accepted Answer

Prednisolone

Answer

Dorzolamide

Answer

Timolol

Answer

Brimonidine

Question 4

Which of the following antidiabetic drugs is NOT an insulin secretagogue?

Accepted Answer

Pramlintide

Answer

Glinides

Answer

Exenatide

Answer

Sulfonylureas

Question 5

What is the primary mechanism of action of propylthiouracil in the treatment of hyperthyroidism?

Accepted Answer

Inhibits iodine organification

Answer

Inhibits the synthesis of thyroglobulin

Answer

Inhibits the release of thyroid hormones T4 and T3

Answer

Inhibits the coupling of iodinated tyrosine residues

Question 6

Non-hormonal drug to prevent postmenopausal osteoporosis is:

Accepted Answer

Alendronate

Answer

Estrogen

Answer

Raloxifene

Answer

Teriparatide

Question 7

The combined estrogen-progestin pill acts mainly by:

Accepted Answer

Suppression of FSH and LH release

Answer

Enhancing uterine contraction to dislodge the fertilized ovum

Answer

Making the endometrium less suitable for implantation

Answer

Thickening of cervical mucus to prevent sperm penetration

Question 8

Which of the following describes the mechanism of action of acarbose?

Accepted Answer

It acts by inhibiting the enzyme alpha-glucosidase

Answer

It reduces post prandial hyperglycemia

Answer

It decreases the progression of impaired tolerance to overt diabetes mellitus

Answer

It can cause hypoglycemia

Question 9

The choice of drug for hyperthyroidism in the first trimester of pregnancy is?

Accepted Answer

Propylthiouracil

Answer

Methimazole

Answer

Carbimazole

Answer

Perchlorate

Question 10

A 15-year-old girl with type 1 diabetes is brought to the emergency department complaining of dizziness. Laboratory findings include severe hyperglycemia, ketoacidosis, and a blood pH of 7.15. To achieve rapid control of severe ketoacidosis, which of the following is the most appropriate drug?

Accepted Answer

Regular insulin

Answer

NPH insulin

Answer

Tolbutamide

Answer

Ultralente insulin

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?